VNDA
Vanda Pharmaceuticals Inc.
$5.87
-3.77%
$353.0M
No data for this timeframe.
Vol
Market Cap$353.0M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders50 funds
Inst. Value$200.0M
Inst. Activity17 buys / 7 sells
Insider Activity0B / 3S
Insider Net $-$1.9M
Reddit Sentiment69° Warm
SEC Reports1
Recent Activity
Dec 12, 2026
fda_pdufa
PDUFA: VNDA — imsidolimab in Generalized Pustular Psoriasis — 2026-12-12
FDA target action date 2026-12-12 for VNDA (Vanda Pharmaceuticals Inc.). Drug: imsidolimab. Indicati
Jun 4, 2026
Insider
McGuire Daniel Patrick was granted 80,000 shares
SVP, GC and Secretary
Jun 4, 2026
Insider
DUGAN RICHARD W was granted 41,600 shares
Director
Jun 4, 2026
Insider
Chrousos Phaedra was granted 41,600 shares
Director
May 6, 2026
SEC
Vanda Pharmaceuticals reported Q1 2026 revenue of $51.7M (+3% YoY), in line with modest growth, but EPS of -$0.82 missed
8-K — Impact 6/10
Inst.
STATE STREET CORP — DOUBLED
3,015,562 shares ($20.8M)
Inst.
MORGAN STANLEY — TRIM
440,794 shares ($3.0M)
Mar 30, 2026
Event
1:23-cv-00152 Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc.
Court ruling from United States District Court for the District of Delaware. Docket: N/A
Price Targets
$14.13
+140.6% upside
Strong Buy
Current $5.87
Low $7.50
Median $14.00
High $21.00
4 analysts
$7.50
$21.00
Analyst Ratings
2Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 5, 2026 | Truist Securities | INITIATE | Buy |
| Feb 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Dec 31, 2025 | B. Riley Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.59 ▲ +3.1% | $-0.71 — $-0.49 | -28% YoY | 4 |
| Next Q | $-0.51 ▲ +3.1% | $-0.60 — $-0.36 | -34% YoY | 4 |
| Current FY | $-2.27 ▲ +2.0% | $-2.68 — $-1.98 | 39% YoY | 4 |
| Next FY | $-0.77 ▲ +12.5% | $-1.32 — $-0.36 | 66% YoY | 4 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $50.3M | — |
| RENAISSANCE TECHNOLOGIES LLC | $26.0M | — |
| STATE STREET CORP | $20.8M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $17.1M | — |
| DIMENSIONAL FUND ADVISORS LP | $12.2M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | McGuire Daniel | A | $0.00 |
| Jun 4, 2026 | DUGAN RICHARD | A | $0.00 |
| Jun 4, 2026 | Chrousos Phaedra | A | $0.00 |
| Jun 4, 2026 | Duncan Charles | A | $0.00 |
| Jun 4, 2026 | Ward Anne | A | $0.00 |
Reddit Sentiment
69°
Warm
Bearish
Neutral
Bullish
50 institutional holders with $200.0M total value (28,928,051 shares) as of 2026-Q1. Top holders: BlackRock,, RENAISSANCE, STATE. Net buying activity: 17 institutions added/increased vs 7 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 7,275,988 | $50.3M | 25.1% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 3,759,559 | $26.0M | 13.0% | — |
| 3 | STATE STREET CORP | 3,015,562 | $20.8M | 10.4% | DOUBLED +138.7% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2,481,491 | $17.1M | 8.6% | — |
| 5 | DIMENSIONAL FUND ADVISORS LP | 1,771,593 | $12.2M | 6.1% | — |
| 6 | TWO SIGMA INVESTMENTS, LP | 1,398,201 | $9.7M | 4.8% | ADD +47.8% |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,014,522 | $7.0M | 3.5% | — |
| 8 | GOLDMAN SACHS GROUP INC | 838,233 | $5.8M | 2.9% | — |
| 9 | CITADEL ADVISORS LLC | 633,354 | $4.4M | 2.2% | ADD +78.5% |
| 10 | MARSHALL WACE, LLP | 596,002 | $4.1M | 2.1% | — |
| 11 | FEDERATED HERMES, INC. | 575,389 | $4.0M | 2.0% | — |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 551,770 | $3.8M | 1.9% | — |
| 13 | MORGAN STANLEY | 440,794 | $3.0M | 1.5% | TRIM -25.7% |
| 14 | VANGUARD FIDUCIARY TRUST CO | 387,964 | $2.7M | 1.3% | — |
| 15 | Connor, Clark & Lunn Investment Management Ltd. | 376,858 | $2.6M | 1.3% | TRIM -49.3% |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 249,300 | $1.7M | 0.9% | — |
| 17 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 241,430 | $1.7M | 0.8% | — |
| 18 | Woodline Partners LP | 207,666 | $1.4M | 0.7% | — |
| 19 | STATE OF WISCONSIN INVESTMENT BOARD | 200,463 | $1.4M | 0.7% | ADD +33.2% |
| 20 | BANK OF AMERICA CORP /DE/ | 191,927 | $1.3M | 0.7% | DOUBLED +135.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | DOUBLED | 1,263,539 | 3,015,562 | +138.7% | $20.8M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 593,023 | 440,794 | -25.7% | $3.0M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 743,546 | 376,858 | -49.3% | $2.6M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 150,542 | 200,463 | +33.2% | $1.4M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 81,414 | 191,927 | +135.7% | $1.3M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 112,395 | 177,581 | +58.0% | $1.2M | 2026-Q1 |
| Invesco Ltd. | ADD | 122,995 | 174,064 | +41.5% | $1.2M | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 61,466 | 161,596 | +162.9% | $1.1M | 2026-Q1 |
| Nuveen, LLC | TRIM | 291,473 | 117,502 | -59.7% | $811.9K | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | ADD | 68,178 | 105,089 | +54.1% | $726.2K | 2026-Q1 |
| Trexquant Investment LP | TRIM | 204,491 | 89,285 | -56.3% | $617.0K | 2026-Q1 |
| FMR LLC | TRIM | 222,269 | 81,086 | -63.5% | $560.3K | 2026-Q1 |
| Mariner, LLC | DOUBLED | 16,829 | 79,854 | +374.5% | $551.8K | 2026-Q1 |
| CWM, LLC | DOUBLED | 26,979 | 77,366 | +186.8% | $534.6K | 2026-Q1 |
| STRS OHIO | DOUBLED | 300 | 69,700 | +23133.3% | $481.6K | 2026-Q1 |
| SEI INVESTMENTS CO | TRIM | 190,261 | 69,295 | -63.6% | $478.8K | 2026-Q1 |
| Cerity Partners LLC | DOUBLED | 30,292 | 68,403 | +125.8% | $472.7K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | DOUBLED | 23,413 | 48,323 | +106.4% | $338.3K | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 25,832 | 32,504 | +25.8% | $222.9K | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | ADD | 20,000 | 30,000 | +50.0% | $207.3K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 481 | 29,906 | +6117.5% | $206.7K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 545 | 12,301 | +2157.1% | $85.0K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 200 | 1,124 | +462.0% | $7.8K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | TRIM | 583 | 330 | -43.4% | $2.3K | 2026-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 662,305 | 978,990 | +47.8% | $8.6M | 2025-Q4 |
9 unique insiders with 12 transactions. Net insider value: -$1.9M ($0.00 bought, $1.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | McGuire Daniel Patrick | SVP, GC and Secretary | AWARD | 80,000 | — | — |
| Jun 4, 2026 | DUGAN RICHARD W | Director | AWARD | 41,600 | — | — |
| Jun 4, 2026 | Chrousos Phaedra | Director | AWARD | 41,600 | — | — |
| Jun 4, 2026 | Duncan Charles Cliff | Director | AWARD | 41,600 | — | — |
| Jun 4, 2026 | Ward Anne Sempowski | Director | AWARD | 41,600 | — | — |
| Jun 4, 2026 | Honore Tage | Director | AWARD | 41,600 | — | — |
| Jun 4, 2026 | Mitchell Stephen Ray | Director | AWARD | 41,600 | — | — |
| May 18, 2026 | Mitchell Stephen Ray | Director | GIFT | 25,836 | — | — |
| Apr 22, 2026 | Duncan Charles Cliff | Director | AWARD | 57,101 | — | — |
| Mar 2, 2026 | Williams Timothy | SVP & General Counsel | SELL | 42,434 | $8.27 | $350.8K |
| Mar 2, 2026 | Polymeropoulos Mihael Hristos | President and CEO | SELL | 156,235 | $8.17 | $1.3M |
| Feb 23, 2026 | Honore Tage | Director | SELL | 30,000 | $8.03 | $240.9K |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 6.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 2 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$14.13 mean target
+140.6% upside
Strong Buy (1.50)
$7.50 Low
$21.00 High
| Metric | Value |
|---|---|
| Current Price | $5.87 |
| Target Low | $7.50 |
| Target Mean | $14.13 |
| Target Median | $14.00 |
| Target High | $21.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.59 | $-0.71 | $-0.49 | -27.7% | +3.1% | 1↑ 4↓ | $0.1B | 17.8% | 4 |
| Next Q 2026-09-30 |
$-0.51 | $-0.60 | $-0.36 | -33.6% | +3.1% | 3↑ 2↓ | $0.1B | 22.9% | 4 |
| Current FY 2026-12-31 |
$-2.27 | $-2.68 | $-1.98 | 39.4% | +2.0% | 3↑ 2↓ | $0.3B | 21.2% | 4 |
| Next FY 2027-12-31 |
$-0.77 | $-1.32 | $-0.36 | 66.0% | +12.5% | 1↑ 3↓ | $0.4B | 36.1% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.588 | |
| 7d ago | $-0.606 | +0.018 |
| 30d ago | $-0.606 | +0.018 |
| 60d ago | $-0.566 | -0.022 |
| 90d ago | $-0.566 | -0.022 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | Truist Securities | INITIATE | — | Buy |
| Feb 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 31, 2025 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Dec 31, 2025 | Jefferies | MAINTAIN | Hold | Hold |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| May 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Apr 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Mar 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Feb 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Jan 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
69°
Warm
Bearish
Neutral
Bullish
4 mentions
3 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 22, 2026 | 3 | 64° Warm | 2 | 0 | 3 |
| Feb 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Why I'll be buying VNDA on Monday morning
▲ 25
💬 30
⚡ 0.7
Why I’ll be buying VNDA on Monday
▲ 1
💬 1
⚡ 0.0
Why I’ll be buying VNDA on Monday
▲ 1
💬 1
⚡ 0.0
$VNDA - Why it will be a big mover starting Monday PM
▲ 29
💬 24
⚡ 0.7
$vnda could be the buy
▲ 1
💬 0
⚡ 0.0
Dec 12, 2026
fda_pdufa
PDUFA: VNDA — imsidolimab in Generalized Pustular Psoriasis — 2026-12-12
FDA target action date 2026-12-12 for VNDA (Vanda Pharmaceuticals Inc.). Drug: imsidolimab. Indication: Generalized Pustular Psoriasis. PDUFA target a
Jun 3, 2026
Clinical Trial
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Trichostatin A (Phase 2)
Trial: Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
Sponsor: Vanda Pharmaceuticals
Phase: Phase 2
May 27, 2026
short_volume
Short Volume: VNDA — 56.3% short (0.3M / 0.6M)
Short: 327,320 | Exempt: 6,056 | TRF Vol: 581,435 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 20, 2026
drug_approval
EMA: Human medicines European public assessment report (EPAR): Iloperidone Vanda Pharmaceuticals, iloperidone, Status: Opinion
Human medicines European public assessment report (EPAR): Iloperidone Vanda Pharmaceuticals, iloperidone, Status: Opinion
May 18, 2026
short_volume
Short Volume: VNDA — 59.8% short (0.3M / 0.5M)
Short: 314,708 | Exempt: 108 | TRF Vol: 525,900 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: VNDA — 69.8% short (0.4M / 0.6M)
Short: 398,626 | Exempt: 8,066 | TRF Vol: 570,697 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: VNDA — 56.6% short (0.6M / 1.1M)
Short: 641,788 | Exempt: 60,385 | TRF Vol: 1,134,475 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
VNDA Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
earnings_calendar
VNDA Q1 2026 Earnings Scheduled — 2026-05-05
Apr 23, 2026
short_volume
Short Volume: VNDA — 57.8% short (0.4M / 0.6M)
Short: 357,728 | Exempt: 346 | TRF Vol: 619,350 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
Phase Phase 3 — TERMINATED
Mar 30, 2026
Enforcement
1:23-cv-00152 Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc.
Court ruling from United States District Court for the District of Delaware. Docket: N/A
Feb 21, 2026
fda_pdufa
PDUFA: VNDA — Bysanti in bipolar I disorder and schizophrenia — 2026-02-21
FDA target action date 2026-02-21 for VNDA (Vanda Pharmaceuticals Inc.). Drug: Bysanti. Indication: bipolar I disorder and schizophrenia. PDUFA target
Jan 7, 2026
fda_pdufa
PDUFA: VNDA — HETLIOZ in jet lag disorder — 2026-01-07
FDA target action date 2026-01-07 for VNDA (Vanda Pharmaceuticals Inc.). Drug: HETLIOZ. Indication: jet lag disorder. FDA expedited re-review of sNDA
Dec 30, 2025
fda_pdufa
PDUFA: VNDA — tradipitant in motion sickness — 2025-12-30
FDA target action date 2025-12-30 for VNDA (Vanda Pharmaceuticals Inc.). Drug: tradipitant. Indication: motion sickness. PDUFA target action date for